Related Experiment Videos
[Brachytherapy in choroidal melanoma].
M Starzycka1, J Słomska, B Romanowska
1Katedry i Kliniki Okulistyki Collegium Medicum UJ w Krakowie.
Klinika Oczna
|July 13, 1999
Summary
Brachytherapy using ruthenium-106 (106Ru) and iodine-125 (125I) shows effectiveness in treating posterior uveal melanoma. Treatment success depends on tumor characteristics, highlighting the importance of isotope selection for intraocular tumors.
Area of Science:
- Ophthalmology
- Oncology
- Radiation Therapy
Background:
- Brachytherapy for intraocular tumors was established in Cracow in the late sixties.
- The center transitioned from Cobalt-60 (60Co) to Ruthenium-106 (106Ru) in 1994 and Iodine-125 (125I) in 1997.
Purpose of the Study:
- To present clinical experiences with 106Ru and 125I brachytherapy for posterior uveal melanoma.
- To evaluate the efficacy of these brachytherapy isotopes in managing intraocular tumors.
Main Methods:
- Retrospective analysis of 164 patients treated with 106Ru (1995-1997) and 19 patients with 125I (1997-1998).
- Patient demographics, tumor characteristics (thickness, location), dosage (60-100 Gy), and adjunctive transpupillary thermotherapy (TTT) were recorded.
- Follow-up ranged from 3 months to 3 years for 106Ru and 1-3 months for 125I.
Main Results:
- With 106Ru, 51.2% of patients showed improvement, 30.5% stabilization, and 18.3% negative results; 9.7% required enucleation.
- Preliminary evaluation of 125I treatment in 19 patients indicated a positive response in 14 cases.
- Treatment efficacy criteria included tumor thickness reduction, increased density, and vessel obliteration.
Conclusions:
- Brachytherapy is a primary treatment modality for posterior uveal melanoma.
- Tumor size and location significantly influence treatment outcomes.
- Careful selection of the radioactive isotope (106Ru or 125I) is crucial for successful brachytherapy.